Biodesix announces first quarter 2022 results and highlights
Boulder, colo.--(business wire)--biodesix, inc. (nasdaq: bdsx), a leading data-driven diagnostic solutions company with a focus in lung disease, today announced its financial and operating results for first quarter ended march 31, 2022 and provided a corporate update. “we are pleased by the progress we continue to make with our core lung diagnostic sales revenue, which grew 17% over the first quarter 2021 despite significant disruption from the covid-19 omicron variant during the first half of the quarter,” said scott hutton, ceo of biodesix. “we recovered quickly from the omicron wave, and march was an all-time high in core lung diagnostic test results delivered. we also added to our therapeutic guidance portfolio with a full commercial launch of the 72-hour blood based genestrat ngs test, introducing flexibility in addressing individual patient and physician needs when considering the most appropriate treatment options for cancer. in addition, we successfully executed several strategic fundraising efforts to further support our growth and recovery resulting in an additional $27.4 million in debt and equity funding subsequent to quarter end, including a restructuring of our milestone payments to integrated diagnostics to provide further financial flexibility.” first quarter 2022 financial results for the three-month period ended march 31, 2022, as compared to the same period of 2021 (where applicable): total revenue of $6.5 million, an expected decrease of 77%, driven primarily by an expected year-over-year decline in covid-19 diagnostic testing due to lower rate of testing compared to the first quarter of 2021: core lung diagnostic revenue of $4.6 million, an increase of 17% driven primarily by growth in the nodify lung nodule management tests; covid-19 testing revenue of $1.0 million, a decrease of 96% in line with expectations as the pandemic recedes and covid testing trends continue to move to at-home testing; biopharma services revenue of $0.9 million, a decrease of 45% driven by disruptions in clinical trials world-wide by the spike in the omicron covid-19 variant; core lung diagnostic revenue of $4.6 million, an increase of 17% driven primarily by growth in the nodify lung nodule management tests; covid-19 testing revenue of $1.0 million, a decrease of 96% in line with expectations as the pandemic recedes and covid testing trends continue to move to at-home testing; biopharma services revenue of $0.9 million, a decrease of 45% driven by disruptions in clinical trials world-wide by the spike in the omicron covid-19 variant; first quarter 2022 gross margin of $3.3 million, or 51% as a percentage of revenue as compared to 37% in the comparable prior year period primarily driven by the mix shift of sales to higher-margin core lung diagnostics and away from lower-margin covid-19 testing partially offset by costs related to the commercial launch of our genestrat ngs™ test in january; operating expenses (excluding direct costs and expenses) of $17.8 million, an increase of 10% driven primarily by growth in sales and marketing to fund our growth in sales and recent genestrat ngs commercial launch; includes non-cash stock compensation expense of $1.3 million as compared to $1.8 million in the prior year quarter; includes non-cash stock compensation expense of $1.3 million as compared to $1.8 million in the prior year quarter; net loss of $15.6 million, an increase of 124%; cash and cash equivalents of $16.4 million as of march 31; included payment of $4.625 million for scheduled milestone payment in january 2022 to integrated diagnostics (indi); included payment of $4.625 million for scheduled milestone payment in january 2022 to integrated diagnostics (indi); liquidity and capital improvements subsequent to march 31, 2022: equity proceeds of $11.7 million from a private placement; equity proceeds of approximately $2.7 million through the at-the-market facility; completion of $25.0 million debt facility of which $15.0 million (approximately $13.0 million, net, after deducting estimated debt issuance costs and original issue discounts) funded in may 2022 and remaining amount contingently available based on contract terms; repayment of $3.0 million in outstanding principal balance on term loan; restructuring of indi milestone payments reducing required payments by approximately $7.5 million and $7.2 million in 2022 and 2023, respectively. equity proceeds of $11.7 million from a private placement; equity proceeds of approximately $2.7 million through the at-the-market facility; completion of $25.0 million debt facility of which $15.0 million (approximately $13.0 million, net, after deducting estimated debt issuance costs and original issue discounts) funded in may 2022 and remaining amount contingently available based on contract terms; repayment of $3.0 million in outstanding principal balance on term loan; restructuring of indi milestone payments reducing required payments by approximately $7.5 million and $7.2 million in 2022 and 2023, respectively. 2022 financial outlook the company reaffirms our 2022 financial outlook and expects to generate between $37.5 million and $39.5 million in total revenue in 2022. conference call and webcast information management will host an investor conference call and webcast today, may 11, 2022 at 8:00 a.m. eastern time. investor dial-in (domestic): 833-665-0678 investor dial-in (international): 929-517-0173 conference id: 7350548 webcast: https://edge.media-server.com/mmc/p/bqdzbx9a an archived replay of the webcast will be available on the company’s website for a period of 90 days. for a full list of biodesix’s press releases and webinars, please visit biodesix.com. about biodesix biodesix is a leading data-driven diagnostic solutions company with a focus in lung disease. the company develops diagnostic tests addressing important clinical questions by combining multi-omics through the power of artificial intelligence. biodesix is the first company to offer eight non-invasive tests for patients with lung diseases. the blood based nodify lung® nodule risk assessment testing strategy, consisting of the nodify xl2® and the nodify cdt® tests, evaluates the risk of malignancy in incidental pulmonary nodules, enabling physicians to better triage patients to the most appropriate course of action. the blood based iqlung™ strategy for lung cancer patients integrates the genestrat ddpcr™ test, the genestrat ngs™ test and the veristrat® test to support treatment decisions across all stages of lung cancer with results in an unprecedented 36-72 hours, expediting time to treatment. biodesix also leverages the proprietary and advanced diagnostic cortex® ai (artificial intelligence) platform, to collaborate with many of the world’s leading biotechnology and pharmaceutical companies to solve complex diagnostic challenges in lung disease. biodesix launched the sars-cov-2 ddpcr™ test, the platelia sars-cov-2 total ab, and the cpass™ sars-cov-2 neutralization antibody test (cpass™ neutralization test kit, genscript, inc,) in response to the global pandemic and virus that impacts the lung and causes covid-19. for more information about biodesix, visit biodesix.com. note regarding forward-looking statements this press release may contain forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the private securities litigation reform act of 1995. all statements contained in this press release other than statements of historical fact, are forward-looking statements. the words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “plan,” “expect,” “predict,” “potential,” “opportunity,” “goals,” or “should,” and similar expressions are intended to identify forward-looking statements. such statements are based on management’s current expectations and involve risks and uncertainties. actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors. biodesix has based these forward-looking statements largely on its current expectations and projections about future events and trends. these forward-looking statements are subject to a number of risks, uncertainties, and assumptions. forward-looking statements may include information concerning the impact of the covid-19 pandemic on biodesix and its operations, it is possible or assumed future results of operations, including descriptions of its revenues, profitability, outlook, and overall business strategy. forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. the company's ability to continue as a going concern could cause actual results to differ materially from those contemplated in this press release and additionally, other factors that could cause actual results to differ materially from those contemplated in this press release can be found in the risk factors section of biodesix’s most recent annual report on form 10-k, filed march 14, 2022 or subsequent quarterly reports on form 10-q during 2022, if applicable. biodesix undertakes no obligation to revise or publicly release the results of any revision to such forward-looking statements, except as required by law. given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. all forward-looking statements are qualified in their entirety by this cautionary statement. biodesix, inc. condensed balance sheets (unaudited) (in thousands, except share data) march 31, 2022 december 31, 2021 assets current assets cash and cash equivalents $ 16,427 $ 32,712 accounts receivable, net of allowance for doubtful accounts of $100 and $158 3,774 3,656 other current assets 7,032 7,245 total current assets 27,233 43,613 non-current assets property and equipment, net 4,028 4,179 intangible assets, net 11,131 11,617 operating lease right-of-use assets 2,219 — goodwill 15,031 15,031 other long-term assets 2,009 1,657 total non-current assets 34,418 32,484 total assets $ 61,651 $ 76,097 liabilities and stockholders' equity current liabilities accounts payable $ 2,120 $ 1,662 accrued liabilities 6,173 7,665 deferred revenue 2,499 1,850 current portion of operating lease liabilities 1,110 — current portion of contingent consideration 17,821 17,764 current portion of notes payable 51 19 other current liabilities 37 — total current liabilities 29,811 28,960 non-current liabilities long-term notes payable, net of current portion 10,055 9,993 long-term operating lease liabilities 1,177 — contingent consideration 12,212 16,028 other long-term liabilities 615 1,389 total non-current liabilities 24,059 27,410 total liabilities 53,870 56,370 commitments and contingencies stockholders' equity preferred stock, $0.001 par value, 5,000,000 shares authorized; 0 (2022 and 2021) shares issued and outstanding — — common stock, $0.001 par value, 200,000,000 shares authorized; 31,889,317 (2022) and 30,789,649 (2021) shares issued and outstanding 32 31 additional paid-in capital 325,308 321,669 accumulated deficit (317,559 ) (301,973 ) total stockholders' equity 7,781 19,727 total liabilities and stockholders' equity $ 61,651 $ 76,097 biodesix, inc. condensed statements of operations (unaudited) (in thousands, except per share data) three months ended march 31, 2022 2021 revenues covid-19 $ 984 $ 23,232 lung diagnostic 4,649 3,963 diagnostic testing revenue 5,633 27,195 biopharma services 915 1,671 total revenues 6,548 28,866 direct costs and expenses 3,235 18,218 research and development 3,206 3,321 sales, marketing, general and administrative 14,487 11,927 change in fair value of contingent consideration — 983 impairment loss on intangible assets 81 — total operating expenses 21,009 34,449 loss from operations (14,461 ) (5,583 ) other (expense) income: interest expense (1,137 ) (651 ) loss on debt extinguishment — (728 ) other income, net 12 1 total other expense (1,125 ) (1,378 ) net loss $ (15,586 ) $ (6,961 ) net loss per share, basic and diluted $ (0.50 ) $ (0.26 ) weighted-average shares outstanding, basic and diluted 31,070 26,604
